2109 related articles for article (PubMed ID: 27192565)
1. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
Anderson AC; Joller N; Kuchroo VK
Immunity; 2016 May; 44(5):989-1004. PubMed ID: 27192565
[TBL] [Abstract][Full Text] [Related]
2. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute
Herrmann M; Schulte S; Wildner NH; Wittner M; Brehm TT; Ramharter M; Woost R; Lohse AW; Jacobs T; Schulze Zur Wiesch J
Front Immunol; 2020; 11():1870. PubMed ID: 32983106
[TBL] [Abstract][Full Text] [Related]
5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
6. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
7. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
8. Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study.
Jin S; Shang Z; Wang W; Gu C; Wei Y; Zhu Y; Yang C; Zhang T; Zhu Y; Zhu Y; Wu J; Ye D
J Immunother; 2023 May; 46(4):154-159. PubMed ID: 37017991
[TBL] [Abstract][Full Text] [Related]
9. Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis.
Lavon I; Heli C; Brill L; Charbit H; Vaknin-Dembinsky A
Front Immunol; 2019; 10():835. PubMed ID: 31134049
[No Abstract] [Full Text] [Related]
10. Increased Expression of Multiple Co-Inhibitory Molecules on Malaria-Induced CD8
Brandi J; Riehn M; Hadjilaou A; Jacobs T
Front Immunol; 2022; 13():878320. PubMed ID: 35874786
[TBL] [Abstract][Full Text] [Related]
11. Expression of immune checkpoints in T cells of esophageal cancer patients.
Xie J; Wang J; Cheng Sh; Zheng L; Ji F; Yang L; Zhang Y; Ji H
Oncotarget; 2016 Sep; 7(39):63669-63678. PubMed ID: 27577071
[TBL] [Abstract][Full Text] [Related]
12. Not All Immune Checkpoints Are Created Equal.
De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
Front Immunol; 2018; 9():1909. PubMed ID: 30233564
[TBL] [Abstract][Full Text] [Related]
13. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors.
Thommen DS; Schreiner J; Müller P; Herzig P; Roller A; Belousov A; Umana P; Pisa P; Klein C; Bacac M; Fischer OS; Moersig W; Savic Prince S; Levitsky V; Karanikas V; Lardinois D; Zippelius A
Cancer Immunol Res; 2015 Dec; 3(12):1344-55. PubMed ID: 26253731
[TBL] [Abstract][Full Text] [Related]
14. On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment.
Tundo GR; Sbardella D; Lacal PM; Graziani G; Marini S
Chemotherapy; 2019; 64(2):62-80. PubMed ID: 31387102
[TBL] [Abstract][Full Text] [Related]
15. Check point inhibitors as therapies for infectious diseases.
Cox MA; Nechanitzky R; Mak TW
Curr Opin Immunol; 2017 Oct; 48():61-67. PubMed ID: 28865357
[TBL] [Abstract][Full Text] [Related]
16. Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis.
Yu Y; Chen Z; Wang Y; Li Y; Lu J; Cui L; Yu Z; Ding Y; Guo C; Zhang X; Shi Y
Int Immunopharmacol; 2021 Jul; 96():107722. PubMed ID: 33965878
[TBL] [Abstract][Full Text] [Related]
17. [The expression and prognostic value of PD-1, TIM-3, LAG-3 and BTLA in extranodal NK/T cell lymphoma].
Nie L; Liu XY; Ma RJ; Yuan XL; Jiang L; Yang J; Hu AX; Li Z; Zhu ZM
Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):598-602. PubMed ID: 34455749
[No Abstract] [Full Text] [Related]
18. Tim-3, Lag-3, and TIGIT.
Joller N; Kuchroo VK
Curr Top Microbiol Immunol; 2017; 410():127-156. PubMed ID: 28900677
[TBL] [Abstract][Full Text] [Related]
19. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation.
Joller N; Anderson AC; Kuchroo VK
Immunity; 2024 Feb; 57(2):206-222. PubMed ID: 38354701
[TBL] [Abstract][Full Text] [Related]
20. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
Datar I; Sanmamed MF; Wang J; Henick BS; Choi J; Badri T; Dong W; Mani N; Toki M; Mejías LD; Lozano MD; Perez-Gracia JL; Velcheti V; Hellmann MD; Gainor JF; McEachern K; Jenkins D; Syrigos K; Politi K; Gettinger S; Rimm DL; Herbst RS; Melero I; Chen L; Schalper KA
Clin Cancer Res; 2019 Aug; 25(15):4663-4673. PubMed ID: 31053602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]